Peptide Pipeline
Asset·Linear peptide

Pemvidutide

Aliases: ALT-801 · GLP-1/glucagon dual agonist

Pemvidutide is a linear peptide targeting GLP-1R, Glucagon receptor, developed by Eli Lilly for undisclosed indications. As of Aug 15, 2024, its highest verified stage is Phase 2.

Phase 2· verified Aug 15, 2024

Identity

Generic name
—
Brand names
—
Development codes
ALT-801
Sponsor / originator
Eli Lilly
Route / formulation
Subcutaneous injection

Development timeline

    Trials

    View all →

    No records found.